Lectin-responsive Alpha-fetoprotein Curability and Prediction of Clinical Course after Treatment of Yolk Sac Tumors

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023648

Enrollment

Unknown

Registered

2019-06-05

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Yolk Sac Tumors

Interventions

Case series:Surgery and/or chemotherapy

Eligibility

Sex/Gender

Female

Age

1 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Aged 1-40 years; 2. Yolk sac tumors of ovary, vagina and other female reproductive organs confirmed by pathology; 3. Life expectancy exceeds 3 months; 4. Normal blood routine, liver and kidney function and urine routine.

Exclusion criteria

Exclusion criteria: 1. History of past or current hepatocellular carcinoma; 2. Unable to complete follow up; 3. Other malignant tumors in the past five years.

Design outcomes

Primary

Measure	Time frame
Lectin-responsive Alpha-fetoprotein;	—

Countries

China

Contacts

Public ContactWang Jinhui

Peking Union Medical College Hospital

wjhpumch@163.com+86 13661286635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026